This is a routine procedural ruling with no material impact on PFE's stock. The underlying patent litigation continues on schedule. Monitor for claim construction rulings or summary judgment motions later in 2026, which could shift settlement leverage.
Price Chart
Executive Summary
A Special Master in the District of Delaware denied GSK's motion to limit Pfizer/BioNTech and Moderna to a combined 10 hours of deposition time for two key inventor witnesses in related patent infringement cases against PFE and MRNA. The ruling preserves each defendant group's full 7-hour deposition entitlement per witness, meaning PFE/BioNTech can conduct independent, uncoordinated depositions of Drs. Geall and Mandl without sharing time with Moderna. This is a procedural discovery ruling with no financial exposure — it keeps the litigation on its current schedule and does not change the merits of the patent claims against PFE.
Court Ruling Details
Key Facts
- Special Master denied GSK's motion to limit PBNT and Moderna to a combined 10 hours of deposition time for two key inventor witnesses (Drs. Geall and Mandl).
- Each defendant group retains the full 7-hour deposition entitlement per witness under Fed. R. Civ. P. 30(d)(1).
- The ruling does not require PBNT and Moderna to coordinate questioning or attend each other's depositions.
- Fact discovery closes July 29, 2026 — the ruling keeps the existing schedule intact.
- No damages, injunction, or financial exposure was awarded or altered by this ruling.
Financial Impact
No financial impact — procedural discovery ruling only.
Risk Factors
- No new risks from this ruling — the patent litigation remains an ongoing overhang but this order does not change its trajectory.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3rrqn0ol-PFE |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | Court Ruling | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 12, 2026 7w ago | Insider Buy | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 12, 2026 7w ago | Insider Cluster | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.55 (+5.13%) |
Aug 5, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.55 (+5.13%) |
Aug 4, 2026 8w ago | 8-K | $25.41 $28.55 | ▲ +12.36% | ▲ +13.60% | $27.55 (+8.40%) |
Jul 31, 2026 9w ago | Court Ruling | $25.01 $27.96 | ▼ −11.80% | ▼ −8.81% | $27.55 (−10.14%) |
Jul 24, 2026 10w ago | Court Ruling | $24.54 $28.07 | ▲ +14.38% | ▲ +10.76% | $27.55 (+12.25%) |
Jul 6, 2026 12w ago | ANALYST-DOWNGRADE | $23.72 $25.01 | ▼ −5.44% | ▼ −6.00% | $27.55 (−16.13%) |
Jun 18, 2026 15w ago | 8-K | $25.21 $25.14 | ▼ −0.28% | ▼ −0.81% | $27.55 (+9.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access